<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Sydney_Australia_Medals skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Sydney Australia/Medals</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navbar navbar-inverse navbar-fixed-top" style="margin-top:15px;"><DIV class="container"><DIV class="navbar-collapse collapse"><UL class="nav navbar-nav navbar-right"><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Team">Team </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Team">About Us</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Attributions">Attributions</A></LI></UL><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Design">Design </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Design">Project Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Applied_Design">Applied Design</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">Integrated Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Entrepreneurship">Entrepreneurship</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Patent_Law">Patent Law</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Description">Project </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Description">Description</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Experiments">Protocols</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Safety">Safety</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Notebook">Notebook</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Results">Results</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Demonstrate">Demonstrate</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Model">Model </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Model">Our Modelling</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Human_Practices">Communications </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/HP/Silver">Human Practices</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Engagement">Engagement</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">Collaborations</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Interlab">Interlab</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Rate_My_Gel">Rate My Gel</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Parts">Parts </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Parts">Our Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Composite_Part">Our Composite Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Basic_Part">Our Basic Parts</A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Improve">Part Improvement</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:Sydney_Australia/Medals">Medals </A></LI><LI><A href="https://2017.igem.org/Team:Sydney_Australia/Medals"> Medals</A></LI></DIV></DIV></DIV><DIV class="container-fluid page-heading" style="margin-top:60px;"><DIV class="row" style="background-color:#e2e2e2;"><DIV class="col-xs-12" style="background-color:#e2e2e2!important;"><DIV class="box"><DIV class="box-content" id="medals"><H1>Medal Criteria</H1><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Select each category to view more information on how we fulfilled medal criteria.</SPAN></P></DIV><DIV class="box-content" id="bronze"><H1 class="tag-title"><CENTER>Bronze Medal Criteria</CENTER></H1><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">How did we achieve this?</SPAN></EM></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We <STRONG>registered</STRONG> and will be <STRONG>attending </STRONG>the Giant Jamboree in November.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We have met all the <STRONG>deliverables</STRONG> requirements:</SPAN></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia">Our wiki is complete</A></SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We have a <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Attributions">project attributions page:</A></SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We will be presenting our <STRONG>team poster</STRONG> at the Jamboree</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">All of our <STRONG>safety forms</STRONG> have been completed</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We handed in our <STRONG>judging form</STRONG></SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We have completed all of our parts pages:</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Parts <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417000">BBa_K2417000</A> to <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417013">BBa_K2417013</A></SPAN></LI></UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We have sent DNA samples to the Registry</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Parts <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417000">BBa_K2417000,</A><A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417001">BBa_K2417001</A>, <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417002">BBa_K2417002</A>, <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417003">BBa_K2417003</A>, <A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417005">BBa_K2417005</A></SPAN></LI><P><SPAN style="font-size: 16.0pt; font-family: Quicksand; text-align=right;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Attributions">Our <STRONG>project attributions</STRONG> page can be found on our wiki</A></SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We <STRONG>contributed </STRONG>by participating in the <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/InterLab">interlab study</A></SPAN></P></DIV><DIV class="box-content" id="silver"><H1 class="tag-title"><CENTER>Silver Medal Criteria</CENTER></H1><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">How did we achieve this?</SPAN></EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><SPAN style="font-family: Quicksand;"><SPAN style="font-size: 24px;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Results">PART VALIDATION</A></SPAN></SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We <STRONG>validated our parts </STRONG>by showing that they work. We performed an ELISA Assay testing for properly folded insulin, and detected expression of Cytoplasmic Proinsulin, Cytoplasmic Winsulin, Ecotin Proinsulin and YncM Winsulin in the cell fractions we expected them to be.</SPAN></P><P> </P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also performed a glucose uptake assay to identify if the insulin and Winsulin we produced was functional.</SPAN></P><P> </P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Multiple insulin-sensitive cell lines were tested for glycogen synthesis and glucose oxidation upon treatment with human insulin and with our insulin analogues. It was found that Ecotin-Proinsulin, Cytoplasmic-Proinsulin and YncM-Winsulin all induced an increase in glycogen synthesis and glucose oxidation, therefore are stimulating the insulin-receptor and functioned as we expected!</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> See our <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Results">Results page </A>for more information </SPAN></P><P><STRONG><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></EM></STRONG></P><P style="text-align: center;"><SPAN style="font-family: Quicksand;"><SPAN style="font-size: 24px;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">COLLABORATION</A></SPAN></SPAN></P><P><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We <STRONG>collaborated </STRONG>with many other iGEM teams in order to get where we are today. We helped the <STRONG><A style="color:#94bdc1" href="https://2017.igem.org/Team:AQA_Unesp">Sao Paulo State University</A></STRONG> team with their work, as they were also focusing on producing insulin. We helped them with data in Australia, and they in turn told us more about the Brazilian situation, as well as sharing knowledge on our <EM>Bacillus</EM> work and using the modelling program MatLab.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also communicated with <STRONG><A style="color:#94bdc1" href="https://2017.igem.org/Team:Bristol">Bristol University</A></STRONG>, and upon learning they had developed a tool for editing the iGEM wiki, we gave it a go and sent them our feedback. They returned the favour by providing us with data about insulin prices in England, which we were finding hard to come by! </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We worked with <STRONG><A style="color:#94bdc1" href="https://2017.igem.org/Team:Cologne-Duesseldorf">Cologne-Dusseldorf</A></STRONG> to contribute to their post-card distribution idea, by both producing a post-card and by distributing their postcards once they arrived. This collaboration worked both </SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">–</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> we all helped one another by distribution each others</SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">’</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> project ideas to otherwise unreasonable parts of the world, a fantastic experience. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We talked with <STRONG><A style="color:#94bdc1" href="https://2017.igem.org/Team:SECA_NZ">Auckland University</A></STRONG> over skype multiple times, and were able to help each other with working on our wikis. We were also excited to host them at our University when a couple of their team members flew over to visit the SBA conference.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also worked with <A style="color:#94bdc1" href="https://2017.igem.org/Team:SVCE_CHENNAI"><STRONG>Chennai </STRONG></A>by exchanging protocols and tips for the lab. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Finally, we worked with <A style="color:#94bdc1" href="https://2017.igem.org/Team:Uppsala"><STRONG>Uppsala </STRONG></A>by participating in their webinar series about the ethics of synthetic biology and intellectual property, which was a fantastic learning experience </SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">–</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> both by us contribution our experiences and hearing what other teams from around the world had to say about our work.  This work contributed significantly to how we approached our work; particularly with how <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Patent_Law">intellectual property</A> affects the ability of iGEM teams to contribute to the open source registry.  </SPAN></P><P> </P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> See our <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Collaborations">Collaborations page</A> for more information </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Silver">HUMAN PRACTICES</A></SPAN></P><P> </P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">As we were developing a therapeutic agent, there were various things that we needed to address to ensure that we delivered a safe, ethical, useful product for the world. On our <A style="color:#94bdc1" src="https://2017.igem.org/Team:Sydney_Australia/HP/Silver">Human Practices page</A> we have discussed these issues and how they have impacted our project in its development. Furthermore, we went out to the general public to discover how close to home the issues we were learning about really are. This survey, though we only had a limited response, gave us great insight into the reality of diabetes treatment in the world. These results then made us reconsider our understanding of the Social Injustices caused by high priced medications. 
</SPAN></P><P> </P></DIV><DIV class="box-content" id="gold"><H1><CENTER>Gold Medal Criteria</CENTER></H1><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">How did we achieve this?</SPAN></EM></P><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></EM></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">INTEGRATED HUMAN PRACTICES</A></SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">In our project it was very important to talk to multiple groups to gain a complete understanding of the issue of insulin accessibility: Type I diabetics dependent on insulin for health and survival, physicians prescribing the insulin, concerned citizens and members of organizations interested in helping those in need. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Our integrated human practices can be broken into <STRONG>three categories</STRONG>: project design, applied design and entrepreneurship.</SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Project Design:</SPAN></STRONG></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Anthony Di Franco from the USA, founder of the <A style="color:#94bdc1" href="http://openinsulin.org/">OpenInsulin</A> project alerted us to the issue and jumpstarted the project as did Meow-Ludo Meow-Meow was another connection linking us to the <A style="color:#94bdc1" href="http://openinsulin.org/">OpenInsulin</A> project, via his group at <A style="color:#94bdc1" href="http://foundry.bio/">BioFoundry</A></SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand; color: black;">Neil Donelan from <A style="color:#94bdc1" href="https://www.insulinforlife.org/">Insulin For Life</A> suggested that we did not need to focus all of our efforts on a thermostable insulin, as human proinsulin is generally stable without refrigeration – so we considered the option of generating proinsulin in a cheap manner</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Jeni, a pharmacist, warned us of the dangers of modifying our insulin excessively, as endocrinologists prefer not to diagnose biosimilars that may induce an allergic reaction in patients</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Len Mancini from <A style="color:#94bdc1" href="http://www.maxpat.com/">Maxwell<SPAN style="font-family: Helvetica;">’s</SPAN></A> Patent and Trademark Attorneys helped us in the design of our Winsulin sequence, to ensure we weren</SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">’</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;">t infringing on any existing pateitns and ensure we can safely submit our sequence to be Open Source</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Edwina Wang </SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">–</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> a Type I diabetic alerted us of the importance of modelling our insulin in order to predict whether it will be short or long-acting. We found that our modelling predicted it would be short acting.</SPAN></LI></UL><P><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></STRONG></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Applied design:</SPAN></STRONG></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Dr David Beran is an expert on the insulin market working at the <A style="color:#94bdc1" href="http://www.unige.ch/medecine/diabetescentre/fr/membres/beran/">Geneva University Hospitals</A> who alerted us to the fact that it will be difficult to enter the insulin market, due to expensive qualifications and licenses required</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">So we went to George XX from <A style="color:#94bdc1" href="http://openinsulin.org/">OpenInsulin</A> who alerted us to the possibilities of crowd-funding, to aid a jump-start of this Open Source project</SPAN></LI></UL><P> </P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Entrepreneurship:</SPAN></STRONG></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Mike Nichols from <A style="color:#94bdc1" href="https://incubate.org.au/">INCUBATE</A> hub at the University of Sydney educated us on the possibilities of creating a start-up company that could fund the initial production of Winsulin and/or a more cheaply produced human proinsulin</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">He also pointed out the value in us targeting a country with an especially high need for insulin, in order to break into the market</SPAN></LI></UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Dr Narcyz Ghinea from <A style="color:#94bdc1" href="http://sydney.edu.au/medicine/people/academics/profiles/narcyz.ghinea.php">The University of Sydney</A>, an expert in access to high cost medicines, assisted us with data on where the money for clinical trials is sourced from, giving us the idea of a potential use of government grants for this open-sourced project</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Neil Donelan from <A style="color:#94bdc1" href="https://www.insulinforlife.org/">Insulin For Life</A> pointed out the value in producing insulin in the countries that need it most, reducing the costs and problems associated with transport</SPAN></LI><P><STRONG><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></EM></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> See our <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">Integrated Human Practices page</A> for more information </SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">PART IMPROVEMENT</SPAN></P><P style="text-align: center;"><STRONG><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We improved previous parts and submitted them to the registry </SPAN></EM></STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;">and have listed them in our <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Parts">parts page</A></SPAN></P><P style="text-align: left;"> </P><P style="text-align: left;"><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Improved Parts</SPAN></EM></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417000">BBa_K2417000</A> Ecotin-Proinsulin</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_K2417001">BBa_K2417001</A> Cytoplasmic-Proinsulin</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="padding-left: 30px;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">which were improving on</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_M39904">BBa_M39904</A> Human Insulin cDNA</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="http://parts.igem.org/Part:BBa_M1877">BBa_M1877</A> human insulin</SPAN></P><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></EM></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Previous parts in the registry encoding </SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">‘</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Human Inuslin</SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">’</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> were either incomplete or did not match human insulin when entered into a BLAST database. It seems as though there were few teams attempting to <STRONG>create human proinsulin (A, B and C-peptide chains) on a single vector</STRONG>, and so our addition of the complete verified human proinsulin coding sequence is an improvement on these previous parts. Furthermore, we have added an <STRONG>N-terminal His tag</STRONG> to our proinsulin constructs, allowing ease of purification using affinity chromatography. Our addition of an <STRONG>arginine residue</STRONG> between the His tag and the proinsulin protein allows simple one-step cleavage and removal of both the C-peptide and the His tag, as all have the same trypsin cleavage site (arginine residue).</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">The addition of the <STRONG>Ecotin tag</STRONG> assists in the expression of proinsulin by inducing its transport to the periplasm, an oxidative environment with reduced proteases, ideal for folding proteins with disulphide bonds such as proinsulin. Furthermore, periplasmic expression allows for a simplified purification procedure, as only the periplasmic fraction is required.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We have also used an <STRONG>extended ribosome binding</STRONG> site with high efficiency of recruitment, which is an improvement on parts entered that were only protein coding sequences. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P> </P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Model">MODELLING</A></SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We created multiple models and used them to direct the path of our project</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We created models of three types: experimental, physiological and economic. In the experimental model we wanted to examine the complexities of optimizing recombinant insulin production from microbes, so we examined the practicality of multiple expression systems. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">A model was produced that took into consideration the multiple energy costs within a cell, and examined the predicted success of multiple expression systems: cytoplasmic expression, periplasmic expression and secretion into the surrounding media. From this model we <STRONG>predicted periplasmic expression</STRONG> to produce the highest yield.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">This first model was based on the <STRONG>experimental work</STRONG> in the lab. We next produced another model that would predict the behavior of our recombinant insulin <STRONG>under human physiological conditions.</STRONG> From this model we predict that our insulin analogue Winsulin will be relatively fast acting compared to human insulin.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Finally, we developed <STRONG>economic models</STRONG> examining the pricing of insulin across different markets. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Demonstrate">DEMONSTRATE YOUR WORK</A></SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We performed an assay mimicking physiological conditions whereby cells were tested with the insulins we produced (that were previously confirmed via ELISA assay). </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We experimented on multiple cell lines, all of which were receptive to insulin, and measured their levels of glycogen synthesis and glucose oxidation after treatment. It was observed that when tested with Ecotin-Proinsulin, Cytoplasmic-Proinsulin and YncM-Winsulin all the cells showed more glycogen synthase and glucose oxidation activity than at basal levels with no insulin added.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Since this mimics the role that insulin plays in the human body, we have demonstrated the functionality of our parts and the success of our project. </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P></DIV><DIV class="box-content" id="special" id="please"><H1 class="tag-title"><CENTER>Special Medal Criteria</CENTER></H1><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Our team also is eligible for a number of special awards: for <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated"><STRONG>Integrated Human Practices</STRONG></A>, <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Engagement"><STRONG>Education and Public Engagement</STRONG></A>, <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Model"><STRONG>Model</STRONG></A>, <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated"><STRONG>Entrepreneurship</STRONG></A> and <A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated"><STRONG>Applied Design</STRONG></A><STRONG>.</STRONG></SPAN></P><P><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></STRONG></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/HP/Gold_Integrated">INTEGRATED HUMAN PRACTICES</A></SPAN></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We utilized input that we received from online communities (insulin users) and professional advisors, to direct our project towards developing a regular Human Insulin due to its ubiquity on the global market, homology to the endogenously produced protein and freedom from intellectual property constraints.</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Key Communications:</SPAN></EM></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We listened to insulin users (via our survey, and communication with charity organisations involved in the distribution of insulin) who told us that ease of use and accessibility was important. From this we tried to include in our design of a novel analogue thermostability, an increased pI to result in maintenance of baseline blood glucose.</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">It also motivated us to try and simplify the purification and production of our Winsulin construct in order to reduce the expense associated with insulin, and make it more accessible to those in need</SPAN></LI></UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also used weekly meetings with the OpenInsulin team to educate ourselves on the realities of open-source production, and develop our potential plan for moving forward.</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">When ReaGent (from Ghent, Belgium) integrated their views into the team we benefited from sharing global perspectives.</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We spoke to patent attorneys at <A style="color:#94bdc1" href="http://www.maxpat.com/">Maxwell's</A> Patent and Trademark Attorneys, whose feedback we fed into the design of our Winsulin construct so as not to encroach on any existing patents</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Our communication with Dr Narcyz Ghinea from <A style="color:#94bdc1" href="http://sydney.edu.au/medicine/people/academics/profiles/narcyz.ghinea.php">The University of Sydney</A>, an expert in access to high cost medicines, assisted us with data on where the money for clinical trials is sourced from, giving us the idea of a potential use of government grants for this open-sourced project</SPAN></LI><P> </P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Engagement">EDUCATION AND PUBLIC ENGAGEMENT</A></SPAN></STRONG></P><P> </P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Engaging with the wider community was a huge focus of our project </SPAN><SPAN style="font-size: 16.0pt; font-family: Helvetica;">–</SPAN><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> both by alerting them to the issue of insulin accessibility and to the massive potential found in synthetic biological solutions</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><EM><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Key Activities:</SPAN></EM></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We participated in the Synthetic Biology Australasia 2017 conference by presenting a talk on our project, opening up a discussion with the Australasian synthetic biologist community</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We partook in the National Science Week at the Australian Museum by running a stall for the Joint Academic Microbiology Seminars (JAMS) group. This event was organized to educate school-aged children on the possibilities of science, especially the biological sciences</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We participated in the Northern Sydney Science Hub, an event held to educate the public on the variety of microorganisms, and to break the stigma of perceived uncleanliness surrounding them</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We invited students from the Mount St Benedicts School into our labs to teach them some basic biochemical and microbiological techniques, to inspire them to consider undertaking a STEM degree</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also joined a weekly meeting with Counter Culture Labs to gain feedback on our project, as their lab aims towards a similar goal</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Our social media presence has been maintained throughout the year, through Facebook, Snapchat and Twitter, allowing us to access the broader community and the community of insulin users alike with our work, and to receive useful feedback at the same time</SPAN></LI></UL><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Model">MODEL</A></SPAN></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Our modelling approach was multi-faceted to address the complex issue of insulin accessibility, which we broke into three main divisions: production, physiological activity and economic status</SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><OL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">To characterise the experimental/production of insulin, we analysed three expression systems: cytoplasmic, periplasmic and secreted</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We interrogated the yield of folded protein predicted by each model, which allowed us to gain insights into the best way to optimize protein production</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">For our physiological model, we identified a link between the thermodynamic and computationally predicted properties of insulin analogues and their action profiles</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We used this to predict characteristics of our novel insulin analogue, Winsulin</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">For our economic modelling we attempted to elucidate the pressures causing insulin price inflation</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We did this via a 50 country analysis on insulin expense and a 10 country breakdown on affordability relative to income bracket</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We used in-depth case studies to attempt to explain anomalies within the data and provide context to outliers</SPAN></LI></OL><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Entrepreneurship">ENTREPRENEURSHIP</A></SPAN></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We communicated with online Diabetes support communities to identify issues with insulin pricing</SPAN></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We identified open-source manufacturing of insulin and the pump associated with it as an interesting, novel solution to tackling the current issues of insulin pricing</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We worked on developing a novel single-chain insulin analogue with simplified purification properties to help reduce the costs of production, and so reduce costs to the consumer</SPAN></LI></UL><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We designed four tiers of functional business models to pursue in the future:</SPAN></P><OL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Open-source solutions</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Small-medium business</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Large corporations</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">State/Public investment</SPAN></LI></OL><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We also communicated with various experts in the field of startup business and the pharmaceutical industry in order to inform our production of these business models</SPAN></P><P><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></STRONG></P><P style="text-align: center;"><STRONG><SPAN style="font-size: 16.0pt; font-family: Quicksand;"><A style="color:#94bdc1" href="https://2017.igem.org/Team:Sydney_Australia/Applied_Design">APPLIED DESIGN</A></SPAN></STRONG></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We designed a novel Single-Chain Analogue based on our research surrounding the issue of insulin affordability. Through:</SPAN></P><UL><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Case studies</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Economic analysis</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Business model design</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Community outreach</SPAN></LI><LI style="font-size: 16.0pt; font-family: Quicksand;color:#3e3f3f;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;">Intellectual Property Rights</SPAN></LI></UL><P style="margin-left: 18.0pt;"><SPAN style="font-size: 16.0pt; font-family: Quicksand;"> </SPAN></P><P><SPAN style="font-size: 16.0pt; font-family: Quicksand;">We spoke to multiple specialists to inform these views, including the authors of the ACCISS report and members of the OpenInsulin project</SPAN></P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>